Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Pharmaceutical and biotechnology manufacturing company Lonza has introduced X-ray powder diffraction (XRPD) into the portfolio of services offered by its Monteggio site, expanding its range of services to include additional information about polymorph and solid-state properties of active pharmaceutical ingredients (APIs).
Micronisation, the process of reducing the average diameter of a solid material’s particles, is a common technique used in the production of APIs and chemicals to increase their efficacy as particles with reduced diameters have higher dissolution rates. However, micronisation is an energetic process and may result in amorphous generation or polymorphic changes. Such changes can compromise the quality and stability of a product as it changes the physicochemical properties. Appropriate identification and characterisation of a materials solid state is crucial when minimizing stability-related challenges. XRPD offers a non-destructive method for the characterisation of crystalline materials.
The addition of XRPD to Lonza’s Monteggio (CH) site will enhance their comprehensive analytical capabilities with the generation of critical data for drug discovery development, and manufacturing. Associate Director, New Product Introduction and MSAT, Salvator Mercuri at Lonza Monteggio commented: “The implementation of XRPD provides additional analytical information, highlighting differences in the solid state of materials before and after micronisation and determining whether additional processing is needed. The XRPD improves our ability to detect solid state changes induced by the micronisation process early in development and allows the problem to be properly addressed before the process is defined. This will ensure that our processes continue to obtain stable products suitable for further processing and formulation.”
Dirk Knapp, Site Head at Lonza Monteggio, stated: “We continue to focus on improving our analytical toolbox to offer a full picture of the quality and stability of crystalline products. The expansion of our analytical capabilities in Monteggio creates a comprehensive offering that brings a multidisciplinary approach to API development and manufacturing.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance